How does **D2D Pillar 2** support product development?

Mxolisi Mathenjwa and Mary Kate Shapley-Quinn CAPRISA & RTI Johannesburg, South Africa August 30th, 2023











D2D Pillar 2

Who are we?



D2D Pillar 2: SBR in Clinical Trials



MATRIX Deputy Director Thes Palanee-Phillips WITS/RHI, South Africa



D2D Pillar 2 Co-Lead and MATRIX-001 Protocol Co-Chair Leila Mansoor, PhD CAPRISA, South Africa



CaSE Scholar Wanzirai Makoni, MPH PZAT, Zimbabwe



D2D Pillar 2 Co-Lead and MATRIX-002 Protocol Co-Chair Alexandra Minnis, PhD RTI, USA



Project Manager Mxolisi Mathenjwa, MA CAPRISA, South Africa



Senior Socio-Behavioral Scientist Cecilia Milford, PhD CAPRISA, South Africa



Senior Research Epidemiologist Elizabeth Montgomery, PhD RTI, USA



Project Manager
Mary Kate ShapleyQuinn, MPH
RTI, USA



Senior Socio-Behavioral Scientist Hilton Humphries, PhD HSRC, South Africa



Project Coordinator
Enyonam Odoom,
MPH
RTI, USA



Project Manager Ellen Luecke, MPH RTI, USA



Pillar 2: Sociobehavioral Research in Clinical Trials

- We work with the clinical trial (CT) teams and product developers to ensure sociobehavioral research (SBR) embedded in each trial is done rigorously and provides valuable feedback...
 - To the product developer
 - To the MATRIX program
 - To the field



Pillar 2: What are our objectives?

- Design and implement SBR components of clinical trials
- Assess product acceptability, end-user experience and preferences; identify barriers and facilitators that may impact acceptability and adherence.
- Identify product attributes and use considerations likely to challenge and/or facilitate adherence and inform implementation of later phase clinical trials.





Role of Pillar 2 in MATRIX clinical trials

Protocol development

- Contributing to study aims and trial
- Planning for when/how SBR data are collected and analyzed
- Integrating social harms/benefits data

Instrument development

- CRFs
- In-depth interview guides

Other materials, like product use instructions

Analysis & dissemination

- Analyzing quantitative and qualitative SBR data
- Providing rapid feedback to PD teams
- Liaising with Pillar 1 to feed into RRN
- Publications and presentations



Role of Pillar 2 in MATRIX clinical trials

Instrument development

- CRFs
- In-depth interview guides

Other materials, like product use instructions

Why have "core" sociobehavioral CRFs in MATRIX?

For each MATRIX clinical trial...

- 1. Allow for a similar understanding of key topics of interest
- 2. Ensure SBR questions asked are evidence-based (where relevant/appropriate)
- 3. Achieve efficiency across trials by having a common/pre-developed set of questions

- Baseline sociodemographics & behaviors
- Comfort with product
- Worries and excitement
- > Ease of use
- > Gains and losses
- Burden
- Adherence
- Discreetness and product use
- > Interest in future use



Journey of a (sociobehavioral) CRF

- Let's start by looking at one sociobehavioral CRF that will be implemented in MATRIX-001
 - (Just 1 section)
- Let's trace back how to see how we ended up with these questions

MATRIX-001: Final behavioral and accep	stability (FU3) CRF	[Visit /]

Note: Information in italics is for the interviewer and will not be read aloud to the participant. All response options should be read aloud to the participant unless shown in italics.

Impact on sex								
INTERVIEWER READS: The next questions ask about whether your use of the [study product] affected your								
sexual behavior and relationship.								
30. Did using the insert affect			Yes	No				
a. How often you had sex				2				
b. Your overall desire to have sex?				2				
c. Your feelings of intimacy or emotional closeness	with your part	ner	1	2				
during sex? If 24=4, skip								
d. The types of sex you engaged in? If 24=4, skip				2				
31. What did you think about this effect of product use?								
Response options included only if selected "yes" in prior		Somewhat	:	Not				
question	Acceptable	acceptable	acc	eptable				
e. How often you had sex	d sex							
f. Your overall desire to have sex	1							
g. Your feelings of intimacy or emotional								
closeness with your partner during sex	1 2			3				
 The types of sex you engaged in 	1 2			3				
32. How did the insert affect your sexual pleasure? If 24=4.								
32. How did the insert affect your sexual pleasure? If 24=4,	I had less sexual pleasure than usual							
skip	I had more sexual pleasure than							
	usual	ire sexuai pie	asure t	nan				
33. How did the insert affect your (main sexual) partner(s)'		at affected						
sexual pleasure? If 24=4, skip	It was not affected They had less sexual pleasure than							
sexual pleasure: IJ 24-4, skip	usual	i less sexual l	pieasui	e tilali				
☐3 They had more sexual pleasure the								
	□₄I do not know							
	41 do 110t	KIIOW						




A long and winding road...

We solicited a broad range of sociobehavioral instruments for our initial "bank"

We grouped together similar measures and organized them within a framework



We assessed and tailored candidate questions, to fit into a CRF format, creating the "core" SBR CRF packet



*Note that "TFA" = Theoretical Framework of Acceptability We coded them to be able to draw similar questions together across these 93 instruments collected

questions from each TFA*
construct (and ones that
did not fit) to determine
best candidates for
MATRIX

Core SBR CRFs are being tailored, now, for each clinical trial

Where did we start?


- 1. Solicited sociobehavioral data collection instruments from array of D2D collaborators
 - 93 instruments collected from multiple studies (MTN-023/027/028/036/ 038/030/034, Quatro, TRIO, HPTN-059/083/084/076/077, PC 957, etc.)

Let's follow a question from the Pop Council 957 study...

		Monthly	CASI ques	tionnaire	tor wome	n			
	ts on sex and in								
	ne following stat								
	acceptable the e			h aspect of yo	ur sexual expe	rience , on a s	cale from 1		
not a	at all acceptable) to 5 (highly a	cceptable).						
32 R	The effect of t	he ring on you	r overall sexua	al desire/sex di	rive				
	1	2	3		4	5	99		
	Not at all	Not accepta	ble Somew	rhat Acce	ptable i	lighly I	Prefer not		
	acceptable		accepta	able	acc	eptable	to answer		
33 R	R The effect of the ring on how often you had sex								
	1	2	3		4	5	99		
	Not at all	Not accepta	ble Somew	rhat Acce	ptable F	lighly i	Prefer not		
	acceptable		accepta	able	acc	eptable	to answer		
34 R	The effect of t	he ring on the	types of sexua	al activity you	engaged in				
	1	2	3	4	5	97	99		
	Not at all	Not	Somewhat	Acceptable	Highly	Not	Prefer		
	acceptable	acceptable	acceptable		acceptable	applicable	not to		
85 R	The effect of all					I a set de .			
א כי	The effect of the	ne ring on nov	aroused/turr 3	a on you we	re during sexua	97	99		
	Not at all	Not	5 Somewhat	4 Acceptable	•	97 Not	99 Prefer		
	acceptable	acceptable	acceptable	Acceptable	Highly acceptable				
	acceptable	acceptable	acceptable		acceptable	applicable	answer		
						(no sexual activity)	allawei		
6 R	The effect of the	ho ring on you	r lovel of vegin	al watnass du	ring coveral act				
IO K	1	2	3	4	ing sexual act	97	99		
	Not at all	Not	Somewhat	Acceptable	Highly	Not	Prefer		
	acceptable	acceptable	acceptable	Acceptable	acceptable				
	acceptable	acceptable	acceptable		acceptable	applicable (no sexual	answer		
						activity)	unswei		
37 R	The effect of the	he ring on you	r cavual nlasci	Ire		uctivity)			
,, ı	1	2	3	4	5	97	99		
	Not at all	Not	Somewhat	Acceptable	Highly	Not	Prefer		
	acceptable	acceptable	acceptable	· icecpitable	acceptable	applicable	not to		
						(no sexual	answer		
						activity)			
88 R	The effect of the	he ring on you	r ability to rea	ch orgasm/clir	nax				
	1	2	3	4	5	97	99		
	Not at all	Not	Somewhat	Acceptable	Highly	Not	Prefer		
	acceptable	acceptable	acceptable		acceptable	applicable	not to		
						(no sexual	answer		
						activity)			
89 R	The effect of the	he ring on how	v comfortable	vaginal sex wa	s for you				
	1	2	3	4	5	97	99		
	Not at all	Not	Somewhat	Acceptable	Highly	Not	Prefer		
	acceptable	acceptable	acceptable		acceptable	applicable			
						(no vaginal	answer		
						sex)			
10 R	The effect of the	he ring on you	r feelings of in	timacy or emo	tional closene	ss with your p	artner		
	during sex								
	1	2	3	4	5	97	99		
	Not at all	Not	Somewhat	Acceptable	Highly	Not	Prefer		
	acceptable	acceptable	acceptable		acceptable	applicable	not to		
						(no sexual	answer		
						activity)			
1 R	The effect of the	he ring on you	r partner's exp	perience of sex	overall				
	1	2	3	4	5	97	99		
	Not at all	Not	Somewhat	Acceptable	Highly	Not	Prefer		
	acceptable	acceptable	acceptable		acceptable	applicable	not to		
						(no sexual	answer		
						activity)			


How did we sort?

- 1. Solicited sociobehavioral data collection instruments from array of D2D collaborators
- 2. All 93 instruments were coded question-by-question in a qualitative coding software to categorize similar questions
 - About 1,230 questions coded!
 - This code, "sexual acceptability" was used for 52 questions, pulling from 20 different source CRFs/questionnaires



Pause: How did we prioritize areas of inquiry?

 Largely based on the expanded Theoretical Framework of Acceptability from Ortblad, et al.




MATRIX

So, how did we categorize questions into that framework?

- Solicited sociobehavioral data collection instruments from array of D2D collaborators
- 2. All 93 instruments were coded question-by-question in a qualitative coding software to categorize similar questions
- 3. Similar questions collected in MURAL organized to align with the guiding framework to allow for sticky-note style categorization and prioritization

So, how did we categorize into that framework?



Whittling down and tailoring for MATRIX

	Effe	Effects on sexual encounter:				Effects on sex and intimacy							
	45.	5. How does taking the tablets affect your sexual pleasure? Increases your sexual pleasure Does not change your sexual				For the following statements, please think about the ring you used over the past month. Please how acceptable the effect of the ring was on each aspect of your sexual experience, on a scale (not at all acceptable) to 5 (highly acceptable).							
REACH			pleasure Decreases your sexual pleasure Did not have sex in past 3 months	ı	957		The effect of the 1 Not at all acceptable The effect of the 1 Not at all	2 Not acceptable	Somewhat acceptable ften you had se	4 Acceptab	ole H acce	eptable 5	99 Prefer not to answer 99 Prefer not
			Participant skipped question	ш	PC		acceptable	·	acceptable	<u> </u>	acce		to answer
					1	34 R	The effect of th	ne ring on the ty	oes of sexual ac	tivity you eng	aged in		
	TRIO/Quatro	How did the ring affect your sexual pleasure? (Read first three responses.) \[\] \	ry partner, ask about	13.	the past m _ More oft _ Less ofte _The same _I did not l Because of month bef _More ofte	nonth? en have vag f using the	1 Not at all acceptable ne vaginal ring, did inal sex in the past	you have vaginal s	acceptable ex more often, le			97 Not applicable (no sexual activity)	99 Prefer not to answer
		☐ 4 Not sure ☐ 5 N/A – Didn't have sex since last visit	Σ		_Less ofter _The same _I did not l		I sex in the past mo	onth					
		$\square_6 N/A - Didn't$ wear the ring during sex											

Core CRFs

- This is what is included in the "core SBR CRF" packet as the template question to be used in each clinical trial
 - Pillar 2 developed Q17 to set the stage for the section
 - Q18 is adapted from PC 957
 - Q19 & 20: pull from MTN-023, MTN-034, TRIO, Quatro

MATRIX: Core FOLLOW-UP ACCEPTABILITY (FU) CRF questions for use in clinical trials Impact on sex [Note: questions included in studies where sexual activity not restricted by protocol] INTERVIEWER READS: The next questions ask about whether your use of the [study product] affected your sexual behavior and relationship. 17. Did using the [study product] affect... Yes a. How often you had sex b. Your overall desire to have sex c. Your feelings of intimacy or emotional closeness with your partner during sex d. The types of sex you engaged in 18. What did you think about this effect of product use? Somewhat Acceptable acceptable Response option only included if selected in prior question acceptable a. How often you had sex b. Your overall desire to have sex Your feelings of intimacy or emotional closeness with your partner during sex d. The types of sex you engaged in Only for vaginally inserted study products It was not affected 19. How did the [product] affect your sexual pleasure? I had less sexual pleasure than 3 I had more sexual pleasure than 20. How did the [product] affect your (main sexual) It was not affected partner(s)' sexual pleasure? 12 They had less sexual pleasure than They had more sexual pleasure than usual ☐4I do not know

So, back to MATRIX-001...

And, by design, what is in the Core is very close to what is shown in the -001 CRFs

 All questions are tailored to ask specifically about the vaginal insert with the study-specific dosing regimen

MATRIX-001: In-Depth Interview Guide

Links to in-depth interview

		Sexual preasurer if 2 : if simp
lease can you tell me how the vaginal insert tted or did not fit into your life?	life when us • Did it have a others? Wit	tments did you have to make to you ling it? any impact on how you engaged wi h your partner? ervous that other people would find

MATRIX-001: Final behavioral and acceptability (FU3) CRF [Visit 7]

Note: Information in italics is for the interviewer and will not be read aloud to the participant. All response options should be read aloud to the participant unless shown in italics.

Impact on sex								
INTERVIEWER READS: The next questions ask about whether your use of the [study product] affected your								
sexual behavior and relationship.								
30. Did usin	ng the insert affect				Yes	No		
a.	How often you had sex				1	2		
b.	Your overall desire to have sex?					2		
	Your feelings of intimacy or emotional	l closeness v	with your part	ner		2		
	during sex? If 24=4, skip							
	The types of sex you engaged in? If 24				1	2		
	id you think about this effect of produc							
	se options included only if selected "yes	s" in prior		Somewha		Not		
questioi			Acceptable	acceptabl	e acc	eptable		
	How often you had sex		1	2	<u></u>			
	Your overall desire to have sex Your feelings of intimacy or emotional		1	2	3			
_								
	closeness with your partner during sex	X	1	2	3			
h.	The types of sex you engaged in							
32 How die	d the insert affect your sexual pleasure	? If 211-1	. It was no	t affected				
skip	the insert affect your sexual pleasure	. 1) 24-4,	2 I had less sexual pleasure than usual					
экір								
			usual					
33. How die	d the insert affect your (main sexual) pa	artner(s)'	It was not affected					
	pleasure? If 24=4, skip	artifici(s)	=-	l less sexual	nleasur	e than		
эсхийг р	neasure. If 24-4, outp		usual	i icaa acxuui	picasai			
ents did voi	u have to make to your		They had	more sexu	al pleasi	ire than		
	a mare to make to your		usual	o. c Scha	o. p.cos.			
ig it?			4 I do not I	cnow				
y impact on how you engaged with								
vour partner	:?							

Many inputs (and some hiccups) along the way!

- In applying the "core" to -001 and -002, PDs & CT hub provided valuable feedback: then, required updates across study-specific & core CRFs
- Critical conversations with PDs helped shape study-specific questions
- Outputs from Pillar 1 activities
 - Design Consultations, Rapid Response Network, Market Segmentation Survey

Sample questions from conversation with Oak Crest to inform instruments for MATRIX-003:

- 1. What would feel most useful to learn from the product development perspective? What will feel like a "successful" learning from SBR in 003?
- 2. Do you have concerns or potential challenges you anticipate users might have with the ring?
- 3. What have you already learned from people who have used the ring?
- 4. What has felt missing from what you've already learned?



Pillar 1 Pillar 2 integration



- Plan to integrate findings from Pillar 1's design consultations into MATRIX clinical trials
 - MATRIX-001 and -002: design consultation findings used to identify priority topics in the finalized IDI guides
 - Clinical trials in development: product-specific findings can inform CRF and IDI guide content
- From clinical trials findings, Pillar 2 to identify potential follow-up questions for Pillar 1's RRN to solicit input and pursue questions in community-based populations
 - Complement to clinical trials with larger sample size of the RRN
 - Pursue clinical trials findings with broader community-based sample

D2D Pillar 2 Contributions to MATRIX

- Continued synergy with Pillar 1 work will help leverage findings from complementary methods and populations to inform MATRIX work
- Quantitative and qualitative data from clinical trials will be used by PDs to help inform next steps for their product (product design, next clinical trials, informational materials, etc.)

All with the goal of ultimately enhancing acceptability, adherence, feasibility, and ease of delivery of HIV prevention products!

Next Up!



MATRIX-001 and -002 teams

- We'll have a session during each training: tomorrowFriday
- We'll see you at site shortly! Next week for South African sites, in the near future for Kenya and US sites
- MATRIX-003
 - Finalizing data collection instruments for upcoming IRB submissions
- MATRIX-004 and beyond!

Acknowledgements



This program was made possible by the generous support of the American people through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the U.S. Agency for International Development (USAID).

The contents in this presentation are those of the presenter and do not necessarily reflect the view of the U.S. President's Emergency Plan for AIDS Relief, the U.S. Agency for International Development or the U.S. Government.







































